Multi-Atlas MRI-Based Striatum Segmentation for $^{123}$I-FP-CIT SPECT (DAT-SPECT) Compared With the Bolt Method and SPECT-Atlas-Based Segmentation Method Toward the Accurate Diagnosis of Parkinson’s Disease/Syndrome

Koji Sohara*, Tetsuro Sekine², Amane Tateno³, Sunao Mizumura⁴, Masaya Suda¹, Takeshi Sakayori³, Yoshiro Okubo³ and Shin-ichiro Kumita¹

¹ Department of Radiology, Nippon Medical School Hospital, Tokyo, Japan, ² Department of Radiology, Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan, ³ Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan, ⁴ Department of Radiology, Omori Medical Center, Toho University, Tokyo, Japan

Aims: This study aimed to analyze the performance of multi-atlas MRI-based parcellation for $^{123}$I-FP-CIT SPECT (DAT-SPECT) in healthy volunteers. The proposed method was compared with the SPECT-atlas-based and Bolt methods. $^{18}$F-FE-PE2I-PET (DAT-PET) was used as a reference.

Methods: Thirty healthy subjects underwent DAT-SPECT, DAT-PET, and 3D-T1WI-MRI. We calculated the striatum uptake ratio (SUR/SBR), caudate uptake ratio (CUR), and putamen uptake ratio (PUR) for DAT-SPECT using the multi-atlas MRI-based method, SPECT-atlas-based method, and Bolt method. In the multi-atlas MRI-based method, the cerebellum, occipital cortex, and whole-brain were used as reference regions. The correlation of age with DAT-SPECT activity and the correlations of SUR/SBR, CUR, and PUR between DAT-SPECT and DAT-PET were calculated by each of the three methods.

Results: The correlation between age and SUR/SBR for DAT-SPECT based on the multi-atlas MRI-based method was comparable to that based on the SPECT-atlas-based method ($r = -0.441$ to $-0.496$ vs. $-0.488$). The highest correlation between DAT-SPECT and DAT-PET was observed using the multi-atlas MRI-based method with the occipital lobe defined as the reference region compared with the SPECT-atlas-based and Bolt methods (SUR, CUR, and PUR: 0.687, 0.723, and 0.676 vs. 0.698, 0.660, and 0.616 vs. 0.655).

Conclusion: Multi-atlas MRI-based parcellation with the occipital lobe defined as the reference region was at least comparable to the clinical methods.

Keywords: $^{123}$I-FP-CIT, $^{18}$F-FE-PE2I, positron emission tomography, semi-quantification, multi-atlas MRI based parcellation, Bolt method, single photon emission computed tomography, dopamine transporter
INTRODUCTION

123I-FP-CIT-SPECT (DAT-SPECT) is widely used for the assessment of degenerative Parkinson’s syndromes, such as Parkinson’s disease (PD), multiple system atrophy, and progressive supranuclear palsy. The tracer accumulation in DAT-SPECT reflects the availability of dopamine transporter (DAT) and thus the functionality of the nigrostriatal dopaminergic neurons (1–4). As a semi-quantitative method for DAT-SPECT, the uptake ratios in the corpus striatum or in more detailed regions, such as putamen and caudate nucleus, have been used. These ratios can be obtained by dividing the uptake in the target regions (e.g., corpus striatum) by those in the reference areas (e.g., cerebellum, occipital cortex, or whole brain). Several approaches have been attempted to provide robust semi-quantification from DAT imaging. In clinical settings, two types of methods, the Bolt method and the SPECT atlas method, are widely used. The Bolt method can serve as a robust, easy-to-use semi-quantification method (5). However, some errors are inevitable in the case of abnormal brain shapes (6). In addition, this approach does not segment the caudate and putamen, resulting in no capability to evaluate the distribution of nigrostriatal dopaminergic neuron changes in the striatum. Compared with the Bolt method, the SPECT atlas method (e.g., DaTQUANT, GE Healthcare, Little Chalfont, UK) can segment the caudate and putamen (7, 8). However, the segmentation may not be accurate because single SPECT template is used. The volume and shape of the striatum vary among subjects. Generally, it is observed that significant volume reduction is proportional to aging (9). One previous study demonstrated that the effect of aging on dopamine receptor availability was overestimated due to the volume reduction (10). To overcome the disadvantages of the current methods described above, Perlaki et al. evaluated the utility of segmentation by using patient-specific T1WI (11). Their method is expected to be easily implemented into clinical workflows because 3D-T1WI-MRI is generally performed as a routine assessment for Parkinson’s diseases and the scan time for it has decreased due to recently developed acceleration techniques (e.g., parallel imaging and compressed sensing). However, they did not compare MRI segmentation to current clinical methods (the Bolt method or SPECT-atlas-based method). In addition, in terms of MRI segmentation, they only used single MRI atlas. One can expect that the MRI segmentation using multi-atlas MRI can improve the accuracy of segmentation (12).

The purpose of this study was to analyze the performance of multi-atlas MRI-based parcellation for DAT-SPECT. The proposed method was compared with the Bolt method and SPECT-atlas-based method, both of which are currently used in clinical settings. 18F-FE-PE2I ([18F]-E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4'-methyl-phenyl) nortropane) for PET (DAT-PET) was used as a reference. 18F-FE-PE2I showed high affinity and high selectivity for DAT, faster kinetics, more favorable metabolism and low production of a radio metabolite with intermediate lipophilicity (13–15). Several studies have confirmed its high correlation to age even in small regions such as caudate and putamen (r = −0.845 and −0.85, respectively) and high discriminative power between PD and healthy controls (16–19). Based on these previous reports, we expected that 18F-FE-PE2I was an excellent imaging tool for in vivo DAT quantification in the entire nigrostriatal tract (17, 18, 20).

MATERIALS AND METHODS

Subjects

The study was approved by the institutional review board of our institution. Thirty healthy volunteers (HVs) aged 31–79 years (mean ± SD, 54.1 ± 14.5; six subjects per age group; 30s, 40s, 50s, 60s, and 70s) were enrolled. All studies were performed between January 2016 and March 2017. None of the subjects had a present or past history of psychiatric, neurological or somatic disorders or of alcohol- or drug-related problems. All subjects were non-smokers. After an explanation of the study, written informed consent was obtained from all participants. All participants underwent 123I-FP-CIT-SPECT (DAT-SPECT), 18F-FE-PE2I-PET (DAT-PET) and 3D-T1WI-MRI within 85 days (21.4 ± 13.2 days).

SPECT Procedures

SPECT imaging was performed using a dual-head SPECT gamma camera (Infinia, GE Healthcare, Milwaukee, WI, USA) equipped with an extended low-energy general-purpose (ELEGPO) collimator (12 mm full width at half maximum; FWHM). All subjects had received an intravenous injection of 123I-FP-CIT (167 MBq) ([123I]-Ioflupane, DaTScanTM, Nihon Mediphysics Corporation, Nishinomiya, Japan) via the antecubital vein in the supine position. Three hours after tracer injection, SPECT data were acquired for 28.5 min over a 360° range in 4° angular steps (90 views) with 855 s/cycle using circularly rotating gamma cameras. The radius of rotation was 14 cm. We used a 3-dimensional ordered subset expectation maximization (3D-OSEM) image reconstruction algorithm (iteration number, 6; subsets, 10) with an eighth-order Butterworth filter with a cut off of 0.55 cycles/cm. The final SPECT images were reconstructed with Chang’s method (Chang’s attenuation correction) into 3.0-mm isotropic voxels using a 128 × 128 matrix with 128 slices parallel to the orbitomeatal line (21, 22). Scatter correction was not used in this study.

PET Procedures

18F-FE-PE2I was synthesized from its precursor, tosylethyl-PE2I, via a nucleophilic fluorination reaction in our cyclotron for PET (HM18, Sumitomo Heavy Industries, Ltd, Tokyo) at the Clinical Imaging Center for Healthcare, Nippon Medical School. PET scans were carried out with an Eminence SET-3000GCT-X scanner (Shimadzu Corp, Kyoto, Japan) to measure regional brain radioactivity. No arterial blood sampling or metabolite analysis was performed. This scanner provides 99 sections with an axial field of view (FOV) of 256 mm. The in-plane and axial spatial resolutions were 3.45 mm FWHM and 3.72 mm FWHM, respectively. A head fixation device was used during the scans. A 10-min transmission scan using a 137Cs point source was performed to correct for attenuation. A dynamic PET scan was
performed for 60 min ($20 \times 9$, $1 \times 5$, $2 \times 4$, $4 \times 11$) after intravenous bolus injection of $^{18}$F-FE-PE2I. The injected radioactivity was 175.0 to 194.0 (185.5 ± 4.2) MBq. We used a filtered back-projection (FBP) image reconstruction algorithm with a second-order Gaussian filter with a cut off of 0.8 mm. Scatter correction was carried out with the hybrid dual-energy window (HDE) method. Motion correction was not used in this study.

**MRI Procedures**

A 1.5 T magnetic resonance (MR) scanner (Intera 1.5 T Achieva Nova, Philips Medical Systems, Best, Netherlands) was used to acquire a high-resolution 3D fast spoiled gradient echo T1WI sequence (180 slices, 1 mm thickness, TR = 9.3 ms, TE = 4.6 ms, flip angle 10°, field of view 25 × 25 cm). The images were used as a reference for drawing volumes of interest (VOIs) on SPECT or PET images.

**Image Analysis**

One neuroradiologist (T.S.) confirmed that no brain abnormalities were present in the subjects. DAT-SPECT uptake was semi-quantified based on three methods: the multi-atlas-based method using MRI, single-atlas-based method using SPECT and Bolt method. In the first two methods, uptake ratios were calculated for DAT-SPECT in the striatum, caudate, and putamen. In the latter method, the specific-to-non-displaceable binding ratio (SBR) was measured as a substitute for specific uptake ratios. The uptake ratios were calculated for DAT-PET in the striatum, caudate, and putamen in a standard manner based on the multi-atlas-based method using MRI (17). For subsequent analyses, the quantified values for DAT-PET were defined as the reference values. The details of the subsequent analyses are described next.

**DAT-SPECT Images Analysis**

**Multi-Atlas-Based Method Using MRI (PNEURO)**

The PNEURO tool (version 4.0, PMOD Technologies Ltd., Zurich, Switzerland) was used for the entire process. The whole processes described below can be performed semi-automatically, without any user interaction. It took ~10 min to perform the analysis for each case. First, rigid transformation between DAT-SPECT and 3D-T1WI was performed. Then, automatic segmentation was performed using subject-specific T1 images,
creating VOIs for each of the striatum and caudate, putamen, and an outline of the cerebellum, occipital cortex and whole brain (excluding the striatum, ventricles and cerebellum) as a reference in each individual participant. To set these VOIs, we used the 1 mm Hammers atlas-N30R83 maximum probability atlas. The atlas map comprised gray matter as determined from segmentation of the subjects’ T1 images into 30 bilateral cortical areas (including the amygdala and hippocampus), five bilateral deep nuclei (caudate, putamen, ventral striatum, thalamus, and pallidum), the bilateral cerebellum and the brainstem. This was accomplished in PNEURO using a pre-defined database of eight normal T1 MRI scans, each of which was knowledge-based hemispheres were then elastically matched to the specified cortical atlas (here, Hammers). After parcellation, the VOIs were warped to SPECT images. SPECT uptake values were measured using MR-based anatomical VOIs to limit the SPECT-active volume in a reproducible manner. VOI-based analysis was then performed to extract specific target uptakes in the striatum, caudate, and putamen. To calculate uptake ratios, we chose the following three regions as a reference region: the cerebellum, occipital cortex and whole brain (excluding deep nuclei, the brainstem, the cerebellum and ventricles). As a result, the uptake ratio of the striatum (SUR), uptake ratio of the putamen (PUR) and uptake ratio of the caudate (CUR) were calculated based on each of the three reference regions. In addition, we also measured the volumes of the striatum, caudate, and putamen; their volumes were calculated by summing the right and left sides. Each semi-quantitative uptake ratio was calculated using the following formula: semi-quantitative uptake ratio = (mean counts in the target VOI)/(mean counts in the reference VOI).

The workflow for studies with DAT-SPECT/PET and T1-MRI in PNEURO is shown in the upper part of Figure 1.

**Single Atlas-Based Method Using SPECT (DaTQUANT)**

DaTQUANT was used for the entire process (7). After SPECT reconstruction, the transaxial slices were used as input for the software. Non-rigid registration was applied to patient-specific SPECT data to match predefined SPECT-atlas data. Predefined template VOIs on the SPECT atlas were automatically positioned...
FIGURE 3 | Age correlation with DAT activity, measured with DAT-SPECT and DAT-PET in the multi-atlas MRI-based method. In each correlation figure, the vertical axis indicates the semi-quantitative uptake for DAT-SPECT measured by the multi-atlas MRI-based method, and the horizontal axis indicates age. There are $3 \times 3$ correlation figure patterns in two different cases: where the target region is the striatum, caudate, or putamen and where the reference area is the cerebellum, occipital lobe or whole brain.

TABLE 2B | Annual decline rate of DAT activity for Age, measured with DAT-SPECT and DAT-PET.

| Radiopharmaceutical | Analysis tool | Reference area | CSF-C | SUR/SBR | CUR | PUR |
|---------------------|---------------|----------------|-------|---------|-----|-----|
| DAT-SPECT           | PNEURO        | Cerebellum      | –     | –0.391  | –0.491 | –0.312 |
|                     |               | Occipital lobe  | –     | –0.386  | –0.488 | –0.306 |
|                     |               | Whole brain     | –     | –0.320  | –0.432 | –0.232 |
|                     | DaTQUANT      | Occipital lobe  | –     | –0.515  | –0.494 | –0.531 |
|                     | DaTView       | Whole brain     | –     | –0.680  | –      | –0.691 |
|                     |               | Whole brain     | +     |         | –      |       |
| DAT-PET             | PNEURO        | Cerebellum      | –     | –0.479  | –0.598 | –0.372 |

SUR, striatum uptake ratio; SBR, specific binding ratio; CUR, caudate uptake ratio; PUR, putamen uptake ratio; CSF-C, cerebrospinal fluid correction.

...in the target regions, including the striatum, caudate, and putamen. The occipital cortex was also segmented as a reference region. The program calculated the SUR, CUR, and PUR as the ratio of each target region to the reference region.

DaTView (DAT-SPECT Analysis)
We used DaTView (Aze, Tokyo, Japan) for the entire process. The procedure was the same as the method proposed by Tossici-Bolt et al. (5). DaTView applies the whole brain, except a region around the basal ganglia, as a reference region. SBR was defined as

$$SBR = \frac{Cs}{Cr},$$

where Cs is the count concentration in the striatum due to specific binding only and Cr is the count concentration in the reference region due to non-specific binding. SBR is calculated from a sufficiently large VOI, including all counts associated with striatal activity, to be independent from the size of the VOI and from the resolution of the SPECT system. In order to avoid extrastriatal heterogeneous tissue counts, an average striatum volume of 11.2 mL was applied. In addition, we also used the cerebrospinal fluid correction (CSF-c) developed by Mizumura and equipped in DaTView to calculate the SBR (23).

DAT-PET Images Analysis
We applied a simplified reference tissue model (14, 19, 24). To obtain semi-quantitative measures of SUR, CUR, and PUR for...
TABLE 3 | Correlation between the SUR/SBR, CUR and PUR of DAT-SPECT and those of DAT-PET.

| Analysis tool | Reference area | CSF-C | SUR/SBR | CUR | PUR |
|---------------|----------------|-------|---------|-----|-----|
|               |                |       | r       | p   | r   | p   |
| PNEURO        | Cerebellum     | –     | 0.648   | <0.001 | 0.688 | <0.001 |
|               | Occipital lobe | –     | 0.687   | <0.001 | 0.723 | <0.001 |
|               | Whole brain    | –     | 0.642   | <0.001 | 0.704 | <0.001 |
| DaTQUANT      | Occipital lobe | –     | 0.698   | <0.001 | 0.660 | <0.001 |
| DaTView       | Whole brain    | –     | 0.655   | <0.001 | 0.616 | <0.001 |
|               | Whole brain    | +     | 0.659   | <0.001 |       |       |

UR, striatum uptake ratio; SBR, specific binding ratio; CUR, caudate uptake ratio; PUR, putamen uptake ratio; CSF-C, cerebrospinal fluid correction.

DAT-PET, static images were created by summing the dynamic scans between 32 and 60 min. The VOIs were created on these summed images with PNEURO. As in the the method used for the PNEURO DAT-SPECT analysis, after parcellation, the MRI and PET data were matched. PET activity values were applied to the MR-based anatomical VOIs to limit the PET-active volume in a reproducible manner. We also calculated 3 sets of semi-quantitative values with the cerebellum as a reference region (14, 17). The workflow for studies with DAT-PET and T1-MRI in PNEURO is shown in the lower part of Figure 1.

Statistical Analysis
To validate the accuracy of DAT-SPECT quantification, the three types of correlations were statistically tested. First, the correlation of age with DAT-SPECT activity in each of the three methods was calculated with Pearson’s correlation coefficient. Second, the correlation between DAT-SPECT and the reference, DAT-PET, in each region (e.g., the striatum, caudate, and putamen) was calculated with Pearson’s correlation coefficient. Third, the correlation between region volume and age and that between region volume and DAT-SPECT activity in each of the three methods were calculated with Pearson’s correlation coefficient. All statistical analyses were performed using IBM SPSS Statistics (Version 25.0, IBM Corp, Armonk, NY, USA).

RESULTS
The PNEURO analysis after parcellation successfully matched MRI and SPECT/PET data for each of the 30 cases. A representative case (53-year-old male) is shown in Figure 2.
Table 1 presents the results for the mean SUR/SBR, CUR and PUR from the DAT-SPECT and DAT-PET analyses. The correlation coefficients (r values) between age and SUR/SBR, CUR and PUR for DAT-SPECT and DAT-PET are presented in Table 2A; those between age and SUR, CUR and PUR for DAT-SPECT and DAT-PET in the PNEURO analyses are shown in Figure 3. Significant correlation between age and each semi-quantitative value was observed, except for SPECT-PUR, in the PNEURO analyses using the cerebellum or whole brain as the reference region. The annual decline rate of DAT activity with age was $-0.232$ to $-0.691\%$ depending on the measurement method (Table 2B). The r values for SUR/SBR, CUR and PUR between DAT-SPECT and DAT-PET are presented in Table 3; those between DAT-SPECT and DAT-PET in the PNEURO analyses are shown in Figure 4. All three types of SPECT semi-quantified values showed significant correlation to the values of PET ($r = 0.616$–$0.723$). In the PNEURO analyses, there was a tendency toward higher correlation when using the occipital lobe as the reference region than when using other regions (i.e., the cerebellum or whole brain). Regarding semi-quantification in the detailed regions (i.e., CUR or PUR), PNEURO using the occipital lobe as the reference region showed higher correlation than DaTQUANT (CUR $0.723$ vs. $0.660$, PUR $0.676$ vs. $0.616$). Table 4A shows the results for the mean volumes of the striatum, caudate, and putamen. The r values indicated higher correlation of the volumes of the striatum, occipital lobe, cerebellum and whole brain to age ($r = -0.519$ to $-0.678$; Table 4B). The percentage volume decrease in these regions was $-0.393$ to $-0.483\%$ (Table 4C). The r values between volume and SUR/SBR, CUR and PUR are presented in Table 4D. The table shows that only one value in the DaTQUANT analysis, PUR, depended on volume, but only slightly ($r = 0.383$, $p = 0.037$).

**DISCUSSION**

In the current study, DAT-SPECT semi-quantification based on multi-atlas MRI-based methods showed comparable to higher correlation to age or DAT-PET values compared with clinically available methods. In multi-atlas-based MRI analyses, the occipital lobe can be used as a reference for more precise semi-quantification than the cerebellum or whole brain. To our knowledge, this is the first study to validate the performance of semi-automatic multi-atlas MRI-based parcellation for DAT-SPECT. Furthermore, in regard to the comparisons between DAT-SPECT and DAT-PET, the current study recruited more age-generalized healthy controls (i.e., a uniform distribution of younger to older ages) than any of the previous studies.

**Correlation Between Age and DAT-SPECT**

Significant correlation was observed between age and all types of semi-quantitative value for DAT-SPECT. The correlation coefficients (r values) in this study showed a tendency to be equal to those in previous studies. In this study, the r values between age and SUR/SBR, CUR, and PUR for DAT-SPECT were $-0.441$ to $-0.665$, $-0.483$ to $-0.608$, and $-0.331$ to $-0.481$, respectively. In previous studies, the r values between age and SUR/SBR, CUR, and PUR for DAT-SPECT were $-0.449$ to $-0.632$, $-0.496$ and $-0.400$, respectively (18, 19, 21, 25, 26). The r values between age and SBR based on the Bolt method were relatively higher than those based on the other methods ($-0.635$ to $-0.665$ vs. $-0.441$ to $-0.496$). It is assumed that the SBR method overestimates the reduction with age because it does not take the age-dependent decline in striatal volume into account (21). We revealed that the striatal volume declined annually (0.393% per year) despite the fact that the Bolt method defines a fixed striatum volume (11.2 mL) (5). DaTQUANT is generally considered to also be vulnerable to atrophy of the target regions. This method transforms the subject's specific target tracer accumulation into a SPECT template. As a result, it could overestimate the decrease in DAT activity in patients because the putamen volume in Parkinson's disease and multiple system atrophy has a tendency to decrease (27, 28). Therefore, MRI-based VOI delineation is necessary for *in vivo* DAT quantification.

**Correlation Between DAT-PET and DAT-SPECT**

DAT-PET has been shown to be an excellent imaging tool for *in vivo* DAT quantification in the entire nigrostriatal tract (13, 14, 20). There are also some studies concerning the performance of DAT-PET for *in vivo* DAT quantification and comparisons of diagnostic value between normal subjects and those with Parkinson’s disease/Parkinsonism (11, 17, 18).
One of the expected merits of DAT-PET with higher spatial resolution is the segmentation of tracer accumulation into caudate and putamen regions. A detailed evaluation based on this segmentation enables differentiation of neurodegenerative Parkinsonism (29, 30). However, in clinical practice, the use of DAT-PET entails higher costs and higher radiation exposure. It is necessary to enhance the utility of DAT-SPECT semi-quantification by combining several methodological approaches, such as accurate VOI delineation and the selection of appropriate reference tissue.

Regarding SUR, the correlation coefficient between the semi-quantitative values for DAT-SPECT and DAT-PET did not significantly differ among the three methods. The multi-atlas MRI-based method is at least comparable to clinical methods for the semi-quantification of this region. Regarding CUR and PUR, in particular, the method showed higher correlation than the SPECT-atlas method (0.723 and 0.676 vs. 0.660 and 0.616). The multi-atlas MRI-based method is expected to be utilized to detect subtle changes of DAT activity in the caudate and putamen, which may impact the diagnosis of Parkinson’s disease/syndrome. This expectation is also supported by previous studies (17, 18).

### Selection of the Reference Region in the Multi-Atlas MRI-Based Method

In the current study, we sought to determine the appropriate reference regions for accurate DAT-SPECT semi-quantification. The occipital cortex proved to be the best region, with stronger correlation to age and DAT-PET compared with the cerebellum or whole brain. In a study with a similar concept to that of the current study, Delva et al. investigated the location of the optimal reference tissues for DAT imaging (17). They recruited nine patients with early Parkinson’s disease and 34 healthy volunteers. All participants underwent DAT-PET with simultaneous acquisition of MRI, which was further used for VOI delineation. The results showed that the occipital cortex may be preferable as the reference region compared with the cerebellum, which supports the results of the current study. Another of their studies also supported the results of the current study (17). It should be noted, however, that our result cannot be translated directly into clinical scans. In our study, only HVs were recruited. In cases with dementia (e.g., dementia with Lewy bodies and Alzheimer’s disease), several brain morphological changes can be present (31–34). Even when complicated morphological changes occur, the multi-atlas MRI-based approach would be useful thanks to its flexibility with respect to multiple outputs. The pre-processing performed for accurate delineation of each brain region enables mapping of the output of the multiple semi-quantification results based on each reference region. In addition, the degree of the atrophy (net volume) in each corresponding target or reference region would be easily obtainable.

### Limitations

The current study has some limitations. First, it is known that $^{18}$F-FE-PE2I is a more selective ligand to DAT than $^{123}$I-FP-CIT. There is concern regarding the difference between the pharmacokinetics of $^{123}$I-FP-CIT and that of $^{18}$F-FE-PE2I. However, previous studies supported high correlation for both of these ligands (17, 18). Second, we applied one of the standard co-registration methods, the mutual information matching algorithm, provided by a single tool (PNEURO) (35–37). Other co-registration algorithms, such as MRtrix and ANTs, may improve or lead to different results (38–41). Further investigations utilizing multiple pipelines should be conducted. Third, the clinical impact of the multi-atlas MRI-based method was not clarified, because we analyzed only normal volunteers and did not assess any subjects with Parkinson’s disease or Parkinsonism. We used the correlation to age and to DAT-PET value as surrogate indices to validate the accuracy of the current method, and this method has been widely accepted in this kind of study (7, 8, 17–19, 21, 25, 26). The multi-atlas MRI-based method is expected to be more useful in disease conditions because it compensates for the difficulty in segmentation in patients with morphological changes or decreased uptake, but further studies should be conducted. Fourth, a PNEURO analysis takes relatively more time (i.e., ∼10 min), though the whole process is performed semi-automatically. This issue will undoubtedly be resolved when computer technology gets better. Fifth, the attenuation correction in DAT-PET was different from that in DAT-SPECT, which might have impacted the correlation between the two tracers. This is an inherent limitation of a comparison study between DAT-PET and DAT-SPECT (17, 18). Sixth, we performed DAT-PET quantification with a simplified reference tissue model without

| Radiopharmaceutical | Analysis tool | Reference area | CSF-C | SUR/SBR | CUR | PUR |
|---------------------|---------------|----------------|-------|---------|-----|-----|
|                     |               |                |       |         |     |     |
|                     |               |                |       | $r$     | $p$ | $r$ | $p$ | $r$ | $p$ |
| DAT-SPECT           | PNUERO        | Cerebellum     | –     | −0.014  | 0.942 | 0.175 | 0.354 | −0.128 | 0.501 |
|                     |               | Occipital lobe | –     | −0.013  | 0.945 | 0.166 | 0.381 | −0.136 | 0.475 |
|                     |               | Whole_brain    | –     | 0.021   | 0.913 | 0.130 | 0.494 | −0.061 | 0.750 |
| DaTOQUANT           |               | Occipital lobe | –     | −0.190  | 0.315 | 0.225 | 0.232 | −0.383 | 0.037 |
| DaTVView            |               | Whole_brain    | –     | 0.081   | 0.672 | 0.108 | 0.569 |       |       |
|                     |               | Whole_brain    | +     | 0.167   | 0.377 | 0.370 | 0.044 | 0.008  | 0.967 |

SUR indicates striatum uptake ratio; SBR, specific binding ratio; CUR, caudate uptake ratio; PUR, putamen uptake ratio; CSF-C, cerebrospinal fluid correction.
motion correction, partial volume correction or dynamic data analysis (14, 19). We tried to maintain the uniformity of the methodology between DAT-PET and DAT-SPECT analysis. The accuracy of the DAT-PET data was partially validated in the current study, as there was sufficient age correlation of DAT-PET data ($r = -0.601$ to $-0.743$) compared with previous studies (18, 19).

**CONCLUSION**

Multi-atlas MRI-based parcellation for DAT-SPECT semi-quantification is at least comparable to the current clinical methods in terms of the correlation to age and to DAT-PET quantification. In this method, the occipital lobe is the best region to use as the reference. The method is expected to provide detailed and robust semi-quantification in the putamen and caudate nucleus regardless of abnormal brain shape or atrophy of brain tissue.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Committee on Clinical Practice of Investigational New Drugs, Nippon Medical School. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**REFERENCES**

1. Makinen E, Joutsu J, Jaakkola E, Nononen T, Johansson I, Pitkonen M, et al. Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT. J Neurol. (2019) 266:826–34. doi: 10.1007/s00415-019-09202-6
2. Kaasinen V, Vahlberg T. Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Ann Neurol. (2017) 82:873–82. doi: 10.1002/ana.25103
3. Albert NL, Unterrainer M, Diemling M, Xiong G, Bartenstein P, Koch W, et al. Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Euro J Nucl Med Mol Imaging. (2016) 43:1315–22. doi: 10.1007/s00259-015-3304-2
4. Ba F, Martin WR. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord. (2015) 21:87–94. doi: 10.1016/j.parkreldis.2014.11.007
5. Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Euro J Nucl Med Mol Imaging. (2006) 33:1491–9. doi: 10.1007/s00259-006-0155-x
6. Iwabuchi Y, Nakahara T, Kameyama M, Yamada Y, Hashimoto M, Ogata Y, et al. Quantitative evaluation of the tracer distribution in dopamine transporter in human brain using PET with 18F-FE-PE2I. Synapse. (2009) 63:871–80. doi: 10.1002/syn.20670
7. Dickson JC, Tossici-Bolt L, Sera T, de Nijs R, Booij J, Bagnara MC, et al. Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Euro J Nucl Med Mol Imaging. (2012) 39:188–97. doi: 10.1007/s00259-011-1884-z
8. Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. Multi-centric database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. (2013) 40:213–27. doi: 10.1007/s00259-012-2276-8
9. Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev. (2006) 30:730–48. doi: 10.1016/j.neubiorev.2006.07.001
10. Smith CT, Crawford JL, Dang LC, Seaman KL, San Juan MD, Vijay A, et al. Partial-volume correction increases estimated dopamine D2-like receptor binding potential and reduces adult age differences. J Cereb Blood Flow Metab. (2019) 39:822–33. doi: 10.1177/027120451881773693
11. Perdikis G, Sekeres S, Orsi G, Papp L, Suha B, Nagy SA, et al. Validation of an automated morphological MRI-based (123I)-FP-CIT SPECT evaluation method. Parkinsonism Relat Disord. (2016) 29:24–9. doi: 10.1016/j.parkreldis.2016.06.001
12. Douaud G, Gaura V, Ribeiro MJ, Lethimonnier F, Maroy R, Verny C, et al. Distribution of grey matter atrophy in Huntington’s disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage. (2006) 32:1562–75. doi: 10.1016/j.neuroimage.2006.05.057
13. Fazio P, Svenningsson P, Cselényi Z, Hallidin C, Farde L, Varrone A. Nigrostriatal dopamine transporter availability in early Parkinson’s disease. Mov Disord. (2018) 33:592–9. doi: 10.1002/mds.27316
14. Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, et al. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. J Nucl Med. (2012) 53:1065–73. doi: 10.2967/jnumed.111.101626
15. Varrone A, Steiger C, Schou M, Takano A, Finnema SJ, Guilloteau D, et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. (2009) 63:871–80. doi: 10.1002/syn.20670
16. Brummer J, Kerstens V, Cselényi Z, Svenningsson P, Sundgren M, Fazio P, et al. Simplified quantification of [18F]FE-PE2I PET in Parkinson’s disease:

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

**FUNDING**

This work was partially supported by Grant-in-Aid for Scientific Research (B), 15H04896, from Ministry of Education, Culture, Sports, Science and Technology (MEXT, Japan).

**ACKNOWLEDGMENTS**

We would like to thank the radiology technicians of the Division of Nuclear Medicine at the Department of Radiology of Nippon Medical School Hospital and the Nippon Medical School Imaging Center for Healthcare for their valuable support: Kuwako Tomoyuki, Kyoji Asano, Shinjiro Yoshida, Junya Tashiro, Satoshi Harashina, Toshio Maki, and Minoru Sakurai.

Frontiers in Medicine | www.frontiersin.org 9 May 2021 | Volume 8 | Article 662233
discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium. *J Cereb Blood Flow Metab.* (2020). doi: 10.1017/S0271678X20988755. [Epub ahead of print].

17. Delva A, Van Weehegaeghe D, van Aalst J, Ceccarini J, Koole M, Baete K, et al. Quantification and discriminative power of [(18)F]-FE-PE2I PET in patients with Parkinson’s disease. *Eur J Nucl Med Mol Imaging* (2020) 47:1913–26. doi: 10.1007/s00259-019-04587-y

18. Jakobson Mo S, Axelsson J, Jonasson L, Larsson O, Ogren MJ, Ogren M, et al. Dopamine transporter imaging with [(18)F]-FE-PE2I PET and [(123)I]FP-CIT SPECT-a clinical comparison. *EJNMMI Res.* (2018) 8:100. doi: 10.1186/s13355-018-0450-0

19. Shingai Y, Tateno A, Arakawa R, Sakayori T, Kim W, Suzuki H, et al. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [(18)F]-FE-PE2I. *Ann Nucl Med.* (2014) 28:220–6. doi: 10.1007/s12443-013-0798-1

20. Fazio P, Svenningson P, Forsberg A, Jonsson EG, Amini N, Nakao R, et al. Quantitative analysis of [(18)F]-(E)-(3-Iododoprop-2-Enyl)-β-carbouluoroethoxy-3β-(4′-Methyl-Phenyl) nortropine binding to the dopamine transporter in Parkinson disease. *J Nucl Med.* (2015) 56:714–20. doi: 10.2967/jnumed.114.152421

21. Matsuda H, Murata M, Mukai Y, Sako K, Ono H, Toyama H, et al. Japanese multicenter database of healthy controls for [(123)I]FP-CIT SPECT. *Euro J Nucl Med Mol Imaging.* (2018) 45:1405–16. doi: 10.1007/s00259-018-3976-5

22. Sohara K, Kiriyama T, Mizumura S, Ishiwata A, Yamazaki M, Kimura K, et al. Diagnostic utility and characteristics of CT-based attenuation correction in brain perfusion SPECT/CT in predicting the exacerbation of Alzheimer changes from mild cognitive impairment utilizing voxel-based statistical analysis in comparison with Chang’s method. *Ann Nucl Med.* (2020) 34:502–11. doi: 10.1111/1342-5200.13744

23. Mizumura S, Nishikawa K, Murata A, Yoshikura K, Ishii N, Kubo T, et al. Improvement in the measurement error of the specific binding ratio in dopamine transporter SPECT imaging due to exclusion of the cerebrospinal fluid fraction using the threshold of voxel RI count. *Ann Nucl Med.* (2018) 32:288–96. doi: 10.1007/s12443-018-1249-9

24. Ito H, Sudo Y, Suhara T, Okubo Y, Hallidin C, Farle L. Error analysis for quantification of [(11)C]FLB 457 binding to extrastriatal D2 dopamine receptors in the human brain. *Neuroimage.* (2001) 13:531–9. doi: 10.1016/S1053-8119(00)00158-7

25. Tossici-Bolt L, Dickson JC, Sera T, Boooj J, Asenbaum-Nan S, Bagnara MG, et al. [(123)I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. *EJNMMI Phys.* (2017) 4:8. doi: 10.1186/s40658-017-0175-6

26. Yamamoto H, Arimura S, Nakanishi A, Shimo Y, Motoi Y, Ishiguro K, et al. Age-related effects and gender differences in Japanese healthy controls for [(123)I] FP-CIT SPECT. *Ann Nucl Med.* (2017) 31:407–12. doi: 10.1016/j.anrad.2017.11.003

27. Sako W, Murakami N, Izumi Y, Kaji R. MRI can detect nigral volume loss in patients with Parkinson’s disease: evidence from a meta-analysis. *J Parkinsons Dis.* (2014) 4:405–11. doi: 10.3233/JPD-130332

28. Sako W, Murakami N, Izumi Y, Kaji R. The difference in putamen volume between MSA and PD: evidence from a meta-analysis. *Parkinsonism Relat Disord.* (2014) 20:873–7. doi: 10.1016/j.parkreldis.2014.04.028

29. Morbelli S, Arnaldi D, Celli E, Raffa S, Donegani Ml, Capitanio S, et al. Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools. *EJNMMI Phys.* (2020) 10:137. doi: 10.1186/s41355-020-00727-w

30. Matesan M, Gaddikeri S, Longfellow K, Miyaoaka R, Eloyeimi S, Elman S, et al. I-123 DaTscan SPECT brain imaging in parkinsonian syndromes: utility of the putamen-to-caudate ratio. *J Neuroimaging.* (2018) 28:629–34. doi: 10.1111/jon.12530

31. Tagawa R, Hashimoto H, Nakanishi A, Kawarada Y, Muramatsu T, Matsuda Y, et al. The relationship between medial temporal lobe atrophy and cognitive impairment in patients with dementia with Lewy bodies. *J Geriatr Psychiatry Neurol.* (2015) 28:249–54. doi: 10.1177/0891988715590210

32. Kril JJ, Macdonald V, Patel S, Pog F, Halliday GM. Distribution of brain atrophy in behavioral variant frontotemporal dementia. *J Neurol Sci.* (2005) 232:83–90. doi: 10.1016/j.jns.2005.02.003

33. Sarro L, Senjem ML, Lundt ES, Przybelski SA, Lesnick TG, Graff-Radford J, et al. Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. *Brain.* (2016) 139:2740–50. doi: 10.1093/brain/aww193

34. Ferreira D, Nordberg A, Westman E. Biological subtypes of Alzheimer disease: a systematic review and meta-analysis. *Neurology.* (2019) 94:436–48. doi: 10.1212/WNL.0000000000009058

35. Tateno A, Sakayori T, Kim WC, Honjo K, Nakayama H, Arakawa R, et al. Comparison of dopamine D3 and D2 receptor occupancies by a single dose of blonanserin in healthy subjects: a positron emission tomography study with [(11)C]-β-PHNO. *Int J Neuropsychopharmacol.* (2018) 21:522–7. doi: 10.1093/ijnppyb/yy004

36. Shingai Y, Tateno A, Arakawa R, Kim WC, Okubo Y. Evaluation of dopamine D3 receptor occupancy by blonanserin using [(11)C]-β-PHNO in schizophrenia patients. *Psychopharmacology (2021) 238:1343–50. doi: 10.1007/s00213-020-05698-3

37. Sekine T, Buck A, Delso G, Ter Voert EE, Huellner M, Veit-Haibach P, et al. Evaluation of atlas-based attenuation correction for integrated PET/MR in human brain: application of a head atlas and comparison to true CT-based attenuation correction. *J Nucl Med.* (2016) 57:215–20. doi: 10.2967/jnumed.115.159228

38. Tournier JD, Smith R, Raffelt D, Tabbara R, Dhollander P, Pietsch M, et al. MTRix3: a fast, flexible and open software framework for medical image processing and visualisation. *Neuroimage.* (2019) 202:116137. doi: 10.1016/j.neuroimage.2019.116137

39. Tustison NJ, Cook PA, Klein A, Song G, Das SR, Duda JT, et al. Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements. *Neuroimage.* (2014) 99:166–79. doi: 10.1016/j.neuroimage.2014.05.044

40. Avants BR, Duda JT, Kim J, Zhang H, Pluta J, Gee JC, et al. Multivariate analysis of structural and diffusion imaging in traumatic brain injury. *Acad Radiol.* (2008) 15:1360–75. doi: 10.1016/j.acra.2008.07.007

41. Grossman M, Eslinger PJ, Troiani V, Anderson C, Avants B, Gee JC, et al. The role of ventral medial prefrontal cortex in social decisions: converging evidence from fmri and frontotemporal lobar degeneration. *Neuropsychologia.* (2010) 48:3505–12. doi: 10.1016/j.neuropsychologia.2010.07.036

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Sohara, Sekine, Tateno, Mizumura, Suda, Sakayori, Okubo and Kumita. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.